P6740
17-苯基-三-去甲前列腺素 F 2α-乙酰胺
≥95%, solid
别名:
比马前列素
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C25H37NO4
化学文摘社编号:
分子量:
415.57
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352211
MDL number:
产品名称
17-苯基-三-去甲前列腺素 F 2α-乙酰胺, ≥95%, solid
InChI
1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1
SMILES string
CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCc2ccccc2
InChI key
AQOKCDNYWBIDND-FTOWTWDKSA-N
assay
≥95%
form
solid
storage temp.
−20°C
Quality Level
Gene Information
human ... PTGFR(5737)
Application
强效 FP 前列腺素受体激动剂在青光眼动物模型中的应用。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Marta Zezula et al.
Journal of pharmaceutical and biomedical analysis, 174, 348-359 (2019-06-17)
A simple, rapid and accurate ultra-high performance liquid chromatographic (UHPLC) method with a UV detection for the determination of the chemical purity and assay of bimatoprost (BT-1) was developed. The chromatographic separation was achieved with the use of an Acquity
Lindsay Machen et al.
Expert opinion on pharmacotherapy, 21(10), 1269-1282 (2020-04-02)
Fixed-combination glaucoma medications have altered the paradigm of ocular hypertension and glaucoma treatment and are in widespread use today. A comprehensive review of fixed-combination medications will help educate and inform providers for optimal patient care. In this review, the authors
Hong Liang et al.
Molecular vision, 15, 1690-1699 (2009-08-28)
Using an established rabbit toxicological model, this in vivo study compared the ocular cytotoxicity of four topical intraocular pressure (IOP)-lowering agents: the commercial benzalkonium chloride (BAC)-containing solutions of 0.005% latanoprost, 0.004% travoprost, 0.03% bimatoprost (containing 0.02%, 0.015%, and 0.005% BAC
Felipe A Medeiros et al.
Ophthalmology, 127(12), 1627-1641 (2020-06-17)
To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10- and 15-μg bimatoprost implant in subjects with open-angle glaucoma (OAG) and ocular hypertension (OHT) after initial and repeated administrations. Randomized, 20-month, multicenter, subject- and efficacy evaluator-masked, parallel-group, phase 3
Hong Liang et al.
The British journal of ophthalmology, 95(6), 869-875 (2011-03-25)
Using an established three-dimensional (3D) toxicological model based on reconstituted human corneal epithelium (HCE), this study investigated the tolerability of four topical intraocular-pressure-lowering agents: the commercial solutions of benzalkonium chloride (BAC)-containing 0.005% latanoprost, 0.004% travoprost, 0.03% bimatoprost containing 0.02%, 0.015%
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持